Physician profile
John E Tveite
NPI 1205919040
$5,740.33
in general payments reported to CMS, 2019-2025
39 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $462 · 2021: $690 · 2022: $1,037 · 2023: $837 · 2024: $930 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.24 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,018.18 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $679.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $608.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $353.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $336.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $325.17 | 2019-2025 | Prolia, Evenity, Otezla |
| Pfizer INC. | $318.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.01 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $223.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.80 | 2021-2025 | |
| Axsome Therapeutics, INC. | $152.69 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $149.76 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $140.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.47 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $109.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tveite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.